#2907544
H351 Ceaptar go bhféadfadh sé a bheith ina chúis le hailse
H351 Suspected of causing cancer
Filter results
Collections
3 results in 2 documents
#2060593
Maidir le hábharthacht meitibilítí sonraithe tríbhúitiolaisín i gcás go raibh tríbhúitiolaisín aicmithe faoi Rialachán (CE) Uimh. 1272/2008 mar ábhar “a d’fhéadfadh a bheith ina chúis le hailse”, an 5 Meitheamh 2015 ghlac Coiste um Measúnú Riosca na Gníomhaireachta Eorpaí Ceimiceán tuairim lena ndeimhnítear nach bhfuil tríbhúitiolaisín le haicmiú mar ábhar “a d’fhéadfadh a bheith ina chúis le hailse”, rud a fhágann go bhfuil an fhaisnéis deimhniúcháin neamhriachtanach.
With regard to the relevance of specified metabolites of terbuthylazine if terbuthylazine was classified under Regulation (EC) No 1272/2008 as ‘suspected of causing cancer’, the Risk Assessment Committee of the European Chemicals Agency adopted on 5 June 2015 an opinion confirming that terbuthylazine is not to be classified as ‘suspected of causing cancer’, rendering the corresponding confirmatory information unnecessary.
#2060591
Ina theannta sin, le Rialachán Cur Chun Feidhme (AE) Uimh. 820/2011, ceanglaíodh ar an iarratasóir faisnéis deimhniúcháin a chur isteach maidir le hábharthacht na meitibilítí MT1, MT13, MT14 agus na meitibilítí neamhaitheanta LM1, LM2, LM3, LM4, LM5 agus LM6 i ndáil le hailse, i gcás go raibh tríbhúitiolaisín aicmithe faoi Rialachán (CE) Uimh. 1272/2008 ó Pharlaimint na hEorpa agus ón gComhairle mar ábhar “a d’fhéadfadh a bheith ina chúis le hailse”.
In addition, Implementing Regulation (EU) No 820/2011 required the applicant to submit confirmatory information as regards the relevance of the metabolites MT1 MT13, MT14 and of the unidentified metabolites LM1, LM2, LM3, LM4, LM5 and LM6 with respect to cancer, if terbuthylazine was classified under Regulation (EC) No 1272/2008 of the European Parliament and of the Council as ‘suspected of causing cancer’.